Purple Biotech (PPBT) Stock Analysis

Purple Biotech (PPBT) is a publicly traded company in the HEALTHCARE sector. It trades at $2.99, carries a market capitalization of $2.79M. This page summarizes the public market data, fundamentals, and frequently asked questions for PPBT, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Purple Biotech currently has a Bullish sentiment score of 0.48.

About Purple Biotech

Purple Biotech Ltd. is a clinical-stage pharmaceutical company based in Rehovot, Israel, dedicated to the development and commercialization of breakthrough therapies for cancer treatment. With a diverse and promising pipeline, the company leverages advanced research techniques to tackle significant unmet needs in oncology, focusing on precision medicine and innovative treatment modalities. As a forward-thinking player in the biopharmaceutical sector, Purple Biotech aims to substantially impro...

GNG Research Analysis

GNG Research scores Purple Biotech (PPBT) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for PPBT.

Frequently Asked Questions

Does PPBT pay dividends?

Purple Biotech (PPBT) does not currently pay a regular dividend.

What is PPBT's market cap?

Purple Biotech (PPBT) has a market capitalization of $2.79M with a current stock price of $2.99.